Evestia Clinical: A Bold New Identity for EMAS Pharma in Oncology Research

Evestia Clinical: Shaping the Future of Clinical Trials

On March 20, 2025, EMAS Pharma unveiled its transformation into Evestia Clinical, marking a significant milestone in its journey as a research leader in clinical trials specifically targeting oncology and rare diseases. This new identity signifies more than just a rebranding; it represents a commitment to growth, innovation, and partnership within the pharmaceutical sector.

The newly minted Evestia Clinical is supported by Kester Capital and is helmed by an experienced leadership team that includes Richard Barfield as Chairman, Lewis Cameron as CEO, Roy Ovel as Chief Commercial Officer, and Carl Hvass as Chief Financial Officer. Their collective experience in the Contract Research Organization (CRO) industry positions Evestia Clinical to effectively pursue opportunities in a rapidly evolving market.

The Inspiration Behind Evestia

The name 'Evestia' derives from the company's ambition to foster transformative advancements in clinical research. This underscores a dedication to positively impacting the healthcare landscape by driving essential progress in trials related to oncology and rare diseases. According to Richard Barfield, “The launch of Evestia Clinical marks an exciting new chapter in our journey,” highlighting the organization’s forward-thinking vision and purpose.

As a specialized CRO, Evestia Clinical aims to tackle the pressing need for innovative methodologies and expedited timelines in clinical trials. The leadership firmly believes that their role is crucial in aiding biotech companies in their quest to bring life-altering therapies to market faster, a necessity in today's healthcare environment.

Mission and Vision

Evestia Clinical's mission is straightforward yet profound: to empower biotech pioneers by offering tailored clinical research solutions that are both expert-led and agile. This flexibility is essential for accelerating the development of groundbreaking therapies, fostering a culture of excellence, integrity, and unwavering commitment to healthcare advancement.

Lewis Cameron stated, “We are committed to providing our clients with the most effective and adaptive clinical trial solutions,” underscoring the organization's dedication to meeting the unique demands of biotech firms engaged in complex research sectors. Evestia Clinical seeks to become the preferred CRO partner, facilitating the speedy delivery of safe and effective medical solutions.

Strategic Growth Plans

The partnership with Kester Capital is crucial as Adam Maidment, a Managing Partner at Kester, remarked on the strategic importance of Evestia Clinical in a fast-growing global market. With more than a decade of investment experience in CROs, Kester Capital's backing catalyzes Evestia's ambitions for organic growth and potential acquisitions.

The market for clinical research is dynamic, with the need for an innovative approach more critical than ever. Evestia Clinical is poised to meet this need by transforming clinical research paradigms, focusing on high-impact areas where clinical studies are most urgently required.

Commitment to Innovation

Innovation lies at the heart of Evestia Clinical's operations. The company recognizes the necessity of combining scientific excellence with patient-centric strategies in order to expedite the pathway of therapies from conception to clinical practice. Evestia Clinical seeks to establish itself not only as a service provider but as a pivotal partner in the journey of biotech companies, facilitating medical breakthroughs that enhance global health outcomes.

In summary, the launch of Evestia Clinical is a bold step forward for the organization, encapsulating its purpose and mission to lead in the highly specialized fields of oncology and rare diseases. This rebranding effort is not merely a change of name; it signifies a renewed focus on delivering high-quality, agile clinical trials. Evestia Clinical is prepared to embrace the challenges of the future, aiding in the development of therapies that could change lives for countless individuals around the world.